{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:01:07Z","timestamp":1789509667406,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Health Commission of Chongqing, China","award":["2016ZDXM010"],"award-info":[{"award-number":["2016ZDXM010"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.intimp.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T13:39:11Z","timestamp":1551965951000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8760-9780","authenticated-orcid":false,"given":"Defeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyun","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2019.03.002_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5114\/pjp.2018.79540","article-title":"Membranous glomerulonephritis - a common, unspecific pattern of glomerular injury","volume":"69","author":"Starzynska-Kubicka","year":"2018","journal-title":"Pol. J. Pathol."},{"issue":"6","key":"10.1016\/j.intimp.2019.03.002_bb0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.intimp.2019.03.002_bb0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000487136","article-title":"The genetic and environmental factors of primary membranous nephropathy: an overview from China","volume":"4","author":"Zhang","year":"2018","journal-title":"Kidney Diseases"},{"key":"10.1016\/j.intimp.2019.03.002_bb0020","unstructured":"Xu X, Wang G, Chen N, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J. Am. Soc. Nephrol.. 2016, 27(12): 3739\u20133746."},{"key":"10.1016\/j.intimp.2019.03.002_bb0025","doi-asserted-by":"crossref","unstructured":"Ren S, Wang Y, Xian L, et al. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: a network meta-analysis. PLoS One. 2017, 12(9): e184398.","DOI":"10.1371\/journal.pone.0184398"},{"key":"10.1016\/j.intimp.2019.03.002_bb0030","doi-asserted-by":"crossref","unstructured":"Zhu L B, Liu L L, Yao L, et al. Efficacy and safety of tacrolimus versus cyclophosphamide for primary membranous nephropathy: a meta-analysis. Drugs. 2017, 77(2): 187\u2013199.","DOI":"10.1007\/s40265-016-0683-z"},{"key":"10.1016\/j.intimp.2019.03.002_bb0035","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"KDIGO Glomerulonephritis Work Group","year":"2012","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.intimp.2019.03.002_bb0040","first-page":"4","volume":"31","year":"2013","journal-title":"Mayo Clin Health Lett."},{"key":"10.1016\/j.intimp.2019.03.002_bb0045","unstructured":"Qiu TT, Zhang C, Zhao HW, et al. Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials. Autoimmun. Rev.. 2017; 16(2): 136\u2013145."},{"key":"10.1016\/j.intimp.2019.03.002_bb0050","series-title":"The Cochrane Collaboration","article-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1016\/j.intimp.2019.03.002_bb0055","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535.","DOI":"10.1136\/bmj.b2535"},{"key":"10.1016\/j.intimp.2019.03.002_bb0060","unstructured":"Fu P, Yuan AH, Yu JP, et al. Mycophenolate mofetil combined with prednisone for treatment of idiopathic membranous nephropathy with nephrotic syndrome: a 36 month prospective controlled study. Acad. J. Second Mil. Univ.. 2012; 33(3): 270\u2013273."},{"key":"10.1016\/j.intimp.2019.03.002_bb0065","doi-asserted-by":"crossref","unstructured":"Yang P, Zou H, Xiao B, et al. Comparative efficacy and safety of therapies in IgA nephropathy: a network meta-analysis of randomized controlled trials. Kidney Int Rep. 2018; 3(4): 794\u2013803.","DOI":"10.1016\/j.ekir.2018.03.006"},{"key":"10.1016\/j.intimp.2019.03.002_bb0070","unstructured":"Li QH, Yang ZJ, Li L, et al. Comparison of efficacy and safety between tacrolimus and cyclosporine combined with corticosteroids in patients with idiopathic membranous nephropathy: a randomized controlled trial. Int. J. Clin. Exp. Med. 2017; 10(6): 9764\u20139770."},{"key":"10.1016\/j.intimp.2019.03.002_bb0075","unstructured":"Peng L, Wei SY, Li LT, et al. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy. J. Formos. Med. Assoc.. 2016; 115(1): 11\u201318."},{"key":"10.1016\/j.intimp.2019.03.002_bb0080","doi-asserted-by":"crossref","unstructured":"He L, Peng Y, Liu H, et al. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids. J Nephrol. 2013; 26(3): 564\u2013571.","DOI":"10.5301\/jn.5000199"},{"key":"10.1016\/j.intimp.2019.03.002_bb0085","unstructured":"Xu J, Zhang W, Xu Y, et al. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib. Nephrol.. 2013; 181: 152\u2013162."},{"key":"10.1016\/j.intimp.2019.03.002_bb0090","doi-asserted-by":"crossref","unstructured":"Chen M, Li H, Li XY, et al. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3): 233\u2013238.","DOI":"10.1097\/MAJ.0b013e3181ca3a7d"},{"key":"10.1016\/j.intimp.2019.03.002_bb0095","doi-asserted-by":"crossref","unstructured":"Chan TM, Lin AW, Tang SCW, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology. 2007; 12(6): 576\u2013581.","DOI":"10.1111\/j.1440-1797.2007.00822.x"},{"issue":"2","key":"10.1016\/j.intimp.2019.03.002_bb0100","first-page":"138","article-title":"Comparison of efficacy and safety between tacrolimus and leflunomide in the treatment of idiopathic membranous nephropathy","volume":"25","author":"Wang","year":"2018","journal-title":"China Modern Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2019.03.002_bb0105","first-page":"1","article-title":"Effect of leflunomide combined with methylprednisolone on idiopathic membranous nephropathy","volume":"39","author":"Shang","year":"2018","journal-title":"Acad J Chin PLA Med Sch"},{"issue":"7","key":"10.1016\/j.intimp.2019.03.002_bb0110","first-page":"1202","article-title":"Long-term efficacy and safety of cyclosporine combined with glucocorticoid in the treatment of idiopathic membranous nephropathy","volume":"23","author":"Huang","year":"2017","journal-title":"Hebei Medicine"},{"issue":"12","key":"10.1016\/j.intimp.2019.03.002_bb0115","first-page":"1238","article-title":"Changes in 24\u202fh urinary protein, serum albumin, serum creatinine of patients with membranous nephropathy in treatment with tacrolimus","volume":"15","author":"Chen","year":"2016","journal-title":"Chin J Diffic and Compl Cas."},{"issue":"5","key":"10.1016\/j.intimp.2019.03.002_bb0120","first-page":"818","article-title":"Comparison on efficacy and safety of tacrolimus and leflunomide combined with hormone in treatment of idiopathic membranous nephropathy","volume":"39","author":"Chang","year":"2016","journal-title":"Drug Evaluation Research"},{"issue":"15","key":"10.1016\/j.intimp.2019.03.002_bb0125","first-page":"2040","article-title":"Efficacy observation of cyclophosphamide, leflunomide sequentially combined with prednisone in the treatment of membranous nephropathy in stage II","volume":"27","author":"Liu","year":"2016","journal-title":"China Pharmacy"},{"issue":"22","key":"10.1016\/j.intimp.2019.03.002_bb0130","first-page":"2181","article-title":"Prognosis of tacrolimus combined with prednisone on patients with idiopathic membranous nephropathy","volume":"31","author":"Zhou","year":"2015","journal-title":"Chin J Clin Pharmacol"},{"key":"10.1016\/j.intimp.2019.03.002_bb0135","series-title":"The Long-term Efficacy and Safety Study of Tacrolimus Combined With Corticosteroids in the Treatment of Idiopathic Membranous Nephropathy","author":"Xu","year":"2015"},{"issue":"20","key":"10.1016\/j.intimp.2019.03.002_bb0140","first-page":"140","article-title":"Intermittent infusion of mycophenolate mofetil or cyclophosphamide in combination with hormone in the treatment of idiopathic membranous nephropathy","volume":"22","author":"Qiu","year":"2014","journal-title":"Chinese Journal of Trauma and Disability Medicine"},{"issue":"13","key":"10.1016\/j.intimp.2019.03.002_bb0145","first-page":"1910","article-title":"Efficacy of cyclosporine A combined with hormone in treatment of membranous nephropathy","volume":"34","author":"Liu","year":"2013","journal-title":"Journal of Qiqihar University of Medicine"},{"key":"10.1016\/j.intimp.2019.03.002_bb0150","series-title":"Clinical Observation of the Tacrolimus Therapy in 30 Cases of Membranous Nephropathy","author":"Xue","year":"2013"},{"key":"10.1016\/j.intimp.2019.03.002_bb0155","series-title":"Clinical Effects of Tacrolimus Division Combined With Glucocorticoids on the Treatment of Idiopathic Membranous Nephropathy","author":"Li","year":"2013"},{"issue":"7","key":"10.1016\/j.intimp.2019.03.002_bb0160","first-page":"797","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in adults with idiopathic membranous nephropathy","volume":"17","author":"Li","year":"2012","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"10.1016\/j.intimp.2019.03.002_bb0165","unstructured":"Wu Y, Zuo K, Wang B, et al. Combination therapy of prednisone and cyclophosphamide for patients with idiopathic membranous nephropathy: a prospective randomized controlled trial. J Nephrol Dialy Transplant. 2012; 21(2): 109\u2013114."},{"key":"10.1016\/j.intimp.2019.03.002_bb0170","unstructured":"Zhang Z, Zhang XT, Ma JW, et al. Efficacy of mycophenolate mofetil combined with low dose hormone in the treatment of membranous nephropathy. Chinese Journal of Integrated Traditional and Western Nephrology. 2011; 12(1): 59\u201360."},{"issue":"1","key":"10.1016\/j.intimp.2019.03.002_bb0175","first-page":"115","article-title":"Medium dose of tacrolimus for idiopathic membranous nephropathy","volume":"14","author":"Wu","year":"2011","journal-title":"China Pharm"},{"issue":"12","key":"10.1016\/j.intimp.2019.03.002_bb0180","first-page":"1889","article-title":"Clinical trial on the effect of leflunomide in treating primary membranous nephropathy","volume":"30","author":"Zhou","year":"2009","journal-title":"Sichuan Medical Journal"},{"issue":"10","key":"10.1016\/j.intimp.2019.03.002_bb0185","first-page":"1674","article-title":"The efficacy of tacrolimus in the treatment of idiopathic membranous nephropathy","volume":"25","author":"Chen","year":"2009","journal-title":"The Journal of practical Medicine"},{"key":"10.1016\/j.intimp.2019.03.002_bb0190","series-title":"The Study on the Treatment of Idiopathic Membranous Nephropathy With Tacrolimus","author":"Liu","year":"2009"},{"issue":"7","key":"10.1016\/j.intimp.2019.03.002_bb0195","first-page":"479","article-title":"Mycophenolate mofetil in the treatment of 20 membranous nephropathy patients","volume":"26","author":"Zhou","year":"2009","journal-title":"Journal of Clinical Internal Medicine"},{"key":"10.1016\/j.intimp.2019.03.002_bb0200","unstructured":"He JF, Huang HP, Wu J, et al. Efficacy of leflunomide combined with prednisone in the treatment of idiopathic membranous nephropathy. Journal of Chinese Practical Diagnosis and Therapy. 2011; 25(12): 1218\u20131219."},{"key":"10.1016\/j.intimp.2019.03.002_bb0205","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Yadav AK, Kumar V, et al. Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide. Kidney Int Rep. 2017; 2(4): 610\u2013616.","DOI":"10.1016\/j.ekir.2017.02.004"},{"key":"10.1016\/j.intimp.2019.03.002_bb0210","doi-asserted-by":"crossref","unstructured":"Ramachandran R, Hn HK, Kumar V, et al. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control tria. Nephrology. 2016; 21(2): 139\u2013146.","DOI":"10.1111\/nep.12569"},{"key":"10.1016\/j.intimp.2019.03.002_bb0215","unstructured":"Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J. Am. Soc. Nephrol.. 2007; 18(6): 1899\u20131904."},{"key":"10.1016\/j.intimp.2019.03.002_bb0220","doi-asserted-by":"crossref","unstructured":"Branten AJ, Reichert LJ, Koene RA, et al. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency. QJM, 1998; 91(5): 359\u2013366.","DOI":"10.1093\/qjmed\/91.5.359"},{"key":"10.1016\/j.intimp.2019.03.002_bb0225","unstructured":"Reichert LJ, Huysmans FT, Assmann K, et al. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann. Intern. Med.. 1994; 121(5): 328\u2013333."},{"key":"10.1016\/j.intimp.2019.03.002_bb0230","unstructured":"Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J. Am. Soc. Nephrol.. 1998; 9(3): 444\u2013450."},{"key":"10.1016\/j.intimp.2019.03.002_bb0235","unstructured":"Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int.. 1995; 48(5): 1600\u20131604."},{"key":"10.1016\/j.intimp.2019.03.002_bb0240","doi-asserted-by":"crossref","unstructured":"Choi JY, Kim DK, Kim YW, et al. The effect of mycophenolate mofetil versus cyclosporine as combination therapy with low dose corticosteroids in high-risk patients with idiopathic membranous nephropathy: a multicenter randomized trial. J. Korean Med. Sci.. 2018; 33(9): e74.","DOI":"10.3346\/jkms.2018.33.e74"},{"key":"10.1016\/j.intimp.2019.03.002_bb0245","unstructured":"Kosmadakis G, Filiopoulos V, Smirloglou D, et al. Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy. Ren. Fail.. 2010; 32(5): 566\u2013571."},{"key":"10.1016\/j.intimp.2019.03.002_bb0250","unstructured":"Naumovic R, Jovanovic D, Pavlovic S, et al. Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: a 3-year prospective study. Biomed. Pharmacother.. 2011; 65(2): 105\u2013110."},{"key":"10.1016\/j.intimp.2019.03.002_bb0255","doi-asserted-by":"crossref","unstructured":"Howman A, Chapman TL, Langdon MM et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet. 2013; 381(9868): 744\u2013751.","DOI":"10.1016\/S0140-6736(12)61566-9"},{"issue":"4","key":"10.1016\/j.intimp.2019.03.002_bb0260","first-page":"560","article-title":"Effective treatment administration of cyclophosphamide in membranous nephropathy","volume":"21","author":"Dede","year":"2008","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.intimp.2019.03.002_bb0265","first-page":"467","article-title":"2014 expert consensus on immunosuppressive treatment for Chinese adults with nephrotic syndrome","volume":"30","author":"Immunosuppressive Treatment for Chinese Adults with Nephrotic Syndrome Work Group","year":"2014","journal-title":"Clin J Nephrol."},{"key":"10.1016\/j.intimp.2019.03.002_bb0270","unstructured":"Wang L, Wang XQ, Shi JH, et al. Cyclosporine in the treatment for idiopathic membranous nephropathy: a meta-analysis. Chin J Clin Healthc. 2015; 18(2): 170\u2013173."},{"issue":"6","key":"10.1016\/j.intimp.2019.03.002_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1399-3062.2008.00346.x","article-title":"New immunosuppressive strategies and the risk of infection","volume":"10","author":"Mueller","year":"2008","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.intimp.2019.03.002_bb0280","doi-asserted-by":"crossref","unstructured":"Peng L, Ma J, Cui R, et al. The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4. PLoS One. 2014; 9(8): e106164.","DOI":"10.1371\/journal.pone.0106164"},{"key":"10.1016\/j.intimp.2019.03.002_bb0285","doi-asserted-by":"crossref","unstructured":"Yamaguchi M, Ando M, Yamamoto R, et al. Patient age and the prognosis of idiopathic membranous nephropathy. PLoS One. 2014, 9(10): e110376.","DOI":"10.1371\/journal.pone.0110376"},{"key":"10.1016\/j.intimp.2019.03.002_bb0290","unstructured":"Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int.. 2002, 61(1): 219\u2013227."},{"key":"10.1016\/j.intimp.2019.03.002_bb0295","doi-asserted-by":"crossref","unstructured":"Yang S, Xie L, Xue W, et al. Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. Nephrology (Carlton), 2013; 18(9): 615\u2013622.","DOI":"10.1111\/nep.12143"},{"issue":"5","key":"10.1016\/j.intimp.2019.03.002_bb0300","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","article-title":"Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate","volume":"19","author":"du Buf-Vereijken","year":"2004","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2019.03.002_bb0305","unstructured":"Capone D, Palmiero G, Gentile A, et al. A pharmacokinetic interaction between clarithromycin and sirolimus in kidney transplant recipient. Curr. Drug Metab.. 2007, 8(4): 379\u2013381."},{"key":"10.1016\/j.intimp.2019.03.002_bb0310","unstructured":"Ishiwata Y, Nagata M, Arai T, et al. Effects of miconazole oral gel on blood concentrations of tacrolimus and cyclosporine: a retrospective observational study. Ther. Drug Monit.. 2016, 38(6): 717\u2013721."},{"key":"10.1016\/j.intimp.2019.03.002_bb0315","unstructured":"Pejcic A, Jankovic S M, Opancina V, et al. Drug-drug interactions in patients receiving hematopoietic stem cell transplantation. Expert Opin. Drug Metab. Toxicol.. 2019, 15(1): 49\u201359."},{"key":"10.1016\/j.intimp.2019.03.002_bb0320","unstructured":"Flather MD, Farkouh ME, Pogue JM, et al. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control. Clin. Trials. 1997; 18(6): 568\u2013579."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918312554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576918312554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T07:07:54Z","timestamp":1556867274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576918312554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":64,"alternative-id":["S1567576918312554"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.03.002","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of infection with different immunosuppressive drugs combined with glucocorticoids for the treatment of idiopathic membranous nephropathy: A pairwise and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}